California Proposition 38 would authorize $8.4 billion in general obligation bonds for immunology and immunotherapy research, directing roughly half the proceeds to a University of California-affiliated nonprofit institute selected under narrow statutory criteria and the balance to competitive grants for other California institutions, with mandates for research on cancer, heart disease, and Alzheimer’s. Trader sentiment favoring rejection reflects documented concerns that the measure’s eligibility rules effectively channel a substantial share of funds to a single donor-supported entity, the California Institute for Immunology and Immunotherapy. Additional headwinds include projected annual General Fund debt service of roughly $500 million for 25 years, uncertainty over revenue offsets from licensing or royalties, and public commentary from scientific policy experts highlighting risks of fragmented state research priorities. These structural and fiscal considerations have sustained the current implied probability against passage ahead of the November 2026 vote.
Experimentelle KI-generierte Zusammenfassung mit Polymarket-Daten. Dies ist keine Handelsberatung und spielt keine Rolle bei der Auflösung dieses Marktes. · AktualisiertJa
54% Chance
NEU
NEU
3. Nov. 2026
Ja
54% Chance
NEU
NEU
3. Nov. 2026
Proposition 38 is a California ballot measure currently scheduled for voting on November 3, 2026. It would allow the state to borrow $8.4 billion in debt to research immune system-based technologies for treating conditions including cancer, heart disease and Alzheimer’s.
This market will resolve to “Yes” if the specified ballot measure is approved by a majority of voters at the California statewide general election currently scheduled for November 3, 2026. Otherwise, this market will resolve to “No.”
If voting on the specified ballot measure does not occur, or the results thereof are not known definitively, by March 31, 2027, this market will resolve to “No”.
This market will resolve based on a consensus of credible reporting. If there is ambiguity, this market will resolve solely based on official information from the State of California, including the California Secretary of State (https://www.sos.ca.gov/).California Proposition 38 would authorize $8.4 billion in general obligation bonds for immunology and immunotherapy research, directing roughly half the proceeds to a University of California-affiliated nonprofit institute selected under narrow statutory criteria and the balance to competitive grants for other California institutions, with mandates for research on cancer, heart disease, and Alzheimer’s. Trader sentiment favoring rejection reflects documented concerns that the measure’s eligibility rules effectively channel a substantial share of funds to a single donor-supported entity, the California Institute for Immunology and Immunotherapy. Additional headwinds include projected annual General Fund debt service of roughly $500 million for 25 years, uncertainty over revenue offsets from licensing or royalties, and public commentary from scientific policy experts highlighting risks of fragmented state research priorities. These structural and fiscal considerations have sustained the current implied probability against passage ahead of the November 2026 vote.
Proposition 38 is a California ballot measure currently scheduled for voting on November 3, 2026. It would allow the state to borrow $8.4 billion in debt to research immune system-based technologies for treating conditions including cancer, heart disease and Alzheimer’s.
This market will resolve to “Yes” if the specified ballot measure is approved by a majority of voters at the California statewide general election currently scheduled for November 3, 2026. Otherwise, this market will resolve to “No.”
If voting on the specified ballot measure does not occur, or the results thereof are not known definitively, by March 31, 2027, this market will resolve to “No”.
This market will resolve based on a consensus of credible reporting. If there is ambiguity, this market will resolve solely based on official information from the State of California, including the California Secretary of State (https://www.sos.ca.gov/).
This market will resolve to “Yes” if the specified ballot measure is approved by a majority of voters at the California statewide general election currently scheduled for November 3, 2026. Otherwise, this market will resolve to “No.”
If voting on the specified ballot measure does not occur, or the results thereof are not known definitively, by March 31, 2027, this market will resolve to “No”.
This market will resolve based on a consensus of credible reporting. If there is ambiguity, this market will resolve solely based on official information from the State of California, including the California Secretary of State (https://www.sos.ca.gov/).
Markt eröffnet: Jul 1, 2026, 6:33 PM ET
Volumen
$2,851Enddatum
3. Nov. 2026Markt eröffnet
Jul 1, 2026, 6:33 PM ETResolver
0x65070BE91...Proposition 38 is a California ballot measure currently scheduled for voting on November 3, 2026. It would allow the state to borrow $8.4 billion in debt to research immune system-based technologies for treating conditions including cancer, heart disease and Alzheimer’s.
This market will resolve to “Yes” if the specified ballot measure is approved by a majority of voters at the California statewide general election currently scheduled for November 3, 2026. Otherwise, this market will resolve to “No.”
If voting on the specified ballot measure does not occur, or the results thereof are not known definitively, by March 31, 2027, this market will resolve to “No”.
This market will resolve based on a consensus of credible reporting. If there is ambiguity, this market will resolve solely based on official information from the State of California, including the California Secretary of State (https://www.sos.ca.gov/).California Proposition 38 would authorize $8.4 billion in general obligation bonds for immunology and immunotherapy research, directing roughly half the proceeds to a University of California-affiliated nonprofit institute selected under narrow statutory criteria and the balance to competitive grants for other California institutions, with mandates for research on cancer, heart disease, and Alzheimer’s. Trader sentiment favoring rejection reflects documented concerns that the measure’s eligibility rules effectively channel a substantial share of funds to a single donor-supported entity, the California Institute for Immunology and Immunotherapy. Additional headwinds include projected annual General Fund debt service of roughly $500 million for 25 years, uncertainty over revenue offsets from licensing or royalties, and public commentary from scientific policy experts highlighting risks of fragmented state research priorities. These structural and fiscal considerations have sustained the current implied probability against passage ahead of the November 2026 vote.
Proposition 38 is a California ballot measure currently scheduled for voting on November 3, 2026. It would allow the state to borrow $8.4 billion in debt to research immune system-based technologies for treating conditions including cancer, heart disease and Alzheimer’s.
This market will resolve to “Yes” if the specified ballot measure is approved by a majority of voters at the California statewide general election currently scheduled for November 3, 2026. Otherwise, this market will resolve to “No.”
If voting on the specified ballot measure does not occur, or the results thereof are not known definitively, by March 31, 2027, this market will resolve to “No”.
This market will resolve based on a consensus of credible reporting. If there is ambiguity, this market will resolve solely based on official information from the State of California, including the California Secretary of State (https://www.sos.ca.gov/).
This market will resolve to “Yes” if the specified ballot measure is approved by a majority of voters at the California statewide general election currently scheduled for November 3, 2026. Otherwise, this market will resolve to “No.”
If voting on the specified ballot measure does not occur, or the results thereof are not known definitively, by March 31, 2027, this market will resolve to “No”.
This market will resolve based on a consensus of credible reporting. If there is ambiguity, this market will resolve solely based on official information from the State of California, including the California Secretary of State (https://www.sos.ca.gov/).
Volumen
$2,851Enddatum
3. Nov. 2026Markt eröffnet
Jul 1, 2026, 6:33 PM ETResolver
0x65070BE91...California Proposition 38 would authorize $8.4 billion in general obligation bonds for immunology and immunotherapy research, directing roughly half the proceeds to a University of California-affiliated nonprofit institute selected under narrow statutory criteria and the balance to competitive grants for other California institutions, with mandates for research on cancer, heart disease, and Alzheimer’s. Trader sentiment favoring rejection reflects documented concerns that the measure’s eligibility rules effectively channel a substantial share of funds to a single donor-supported entity, the California Institute for Immunology and Immunotherapy. Additional headwinds include projected annual General Fund debt service of roughly $500 million for 25 years, uncertainty over revenue offsets from licensing or royalties, and public commentary from scientific policy experts highlighting risks of fragmented state research priorities. These structural and fiscal considerations have sustained the current implied probability against passage ahead of the November 2026 vote.
Experimentelle KI-generierte Zusammenfassung mit Polymarket-Daten. Dies ist keine Handelsberatung und spielt keine Rolle bei der Auflösung dieses Marktes. · Aktualisiert
Vorsicht bei externen Links.
Vorsicht bei externen Links.
Häufig gestellte Fragen